Abstract
Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Current Drug Safety
Title: Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Volume: 3 Issue: 1
Author(s): Luis Garcia-Marcos, Jose A. Ros-Lucas and Manuel Sanchez-Solis
Affiliation:
Keywords: Adverse effects, asthma, inhaled corticosteroids, safety
Abstract: Inhaled corticosteroids (ICS) are the cornerstone of asthma management both in adults and in children. There are some adverse effects related to the use of these drugs in all ages. Those adverse effects can be local or systemic. From the paediatric point of view, the main worry relates to the effect on growth and on the integrity of the HPA-axis. At the recommended doses, their effect on the latter is not clinically relevant and the slight modification of cortisol levels which occurs while taking them reflects their presence in blood. Although there is a slowing down on growth velocity, this is reduced to the first months of treatment which are followed by a catch up: there is quite consistent data supporting their lack of significant effect on the final height. Other adverse effects which may appear in relation to ICS treatment in children, including infants, are mild or very sporadic. However, it is important to bear in mind that a small proportion of asthmatic children may have a certain idiosyncrasy which makes them especially sensitive to ICS. Furthermore, a close follow up is warranted when, due to the disease severity, higher than the recommended doses of ICS are administered.
Export Options
About this article
Cite this article as:
Garcia-Marcos Luis, Ros-Lucas A. Jose and Sanchez-Solis Manuel, Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783334005
DOI https://dx.doi.org/10.2174/157488608783334005 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stem Cells in Stroke Repair: Current Success & Future Prospects
CNS & Neurological Disorders - Drug Targets Simultaneous Quantitative Determinations of Fluticasone Propionate and Salmeterol Xinafote in Diskus Inhalers
Drug Metabolism Letters Advances in Whole Genome Sequencing Technology
Current Pharmaceutical Biotechnology Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?
Current Protein & Peptide Science Can We Delay the Accelerated Lung Aging in COPD? Anti-Aging Molecules and Interventions
Current Drug Targets Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Current Drug Targets Epigenetics of Aging
Current Genomics Natural Products and their (Semi-)Synthetic Forms in the Treatment of Migraine: History and Current Status
Current Medicinal Chemistry Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology A<sub>2A</sub> Adenosine Receptor Antagonists in Neurodegenerative Diseases
Current Medicinal Chemistry Enteric Coated Guar Gum Microspheres of Ornidazole for Colonic Delivery
Current Nanoscience cAMP Signalling in the Kinetoplastid Protozoa
Current Molecular Medicine Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Metabolomics of Exhaled Breath Condensate by Nuclear Magnetic Resonance Spectroscopy and Mass Spectrometry: A Methodological Approach
Current Medicinal Chemistry Idiopathic Pulmonary Fibrosis: An EU Patient Perspective Survey
Current Respiratory Medicine Reviews Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design The C-Terminal Domain of Pancreatic Lipase: Functional and Structural Analogies with C2 Domains
Current Protein & Peptide Science Start Small and Stay Small: Minimizing Attrition in the Clinic with a Focus on CNS Therapeutics
Current Topics in Medicinal Chemistry Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Current Pharmaceutical Design